ABOUT

Our research group focuses on understanding how molecular and microbial factors shape cancer development, progression, and treatment response. We investigate the microbiome–epigenome–DNA repair axis, a critical intersection where genetic variation, chromatin remodeling, DNA damage response, and cervicovaginal microbial ecology converge to influence cancer behavior, particularly in women’s cancers.

We explore how pharmacogenetic variation, epigenetic drift, and DNA repair dysfunction drive therapy sensitivity or resistance. By integrating genomics, epigenomics, transcriptomics, and microbiome profiling with clinical outcome data, our group aims to identify biomarkers that can reliably predict who benefits from treatment and who may require alternative therapeutic strategies.

With a strong commitment to women’s health, we focus on cervical cancer, HPV biology, host–microbe interactions, and translational applications designed for diverse and underserved populations.

Our long-term goal is to advance precision and predictive oncology, transforming mechanistic insights into practical tools that improve cancer diagnosis, guide individualized treatment decisions, and enhance patient outcomes.